Repurposing the clinically approved calcium antagonist manidipine dihydrochloride as a new early inhibitor of human cytomegalovirus targeting the Immediate‐Early 2 (IE2) protein

@article{Mercorelli2018RepurposingTC,
  title={Repurposing the clinically approved calcium antagonist manidipine dihydrochloride as a new early inhibitor of human cytomegalovirus targeting the Immediate‐Early 2 (IE2) protein},
  author={Beatrice Mercorelli and Anna Luganini and Marta Celegato and Giorgio Pal{\`u} and Giorgio Gribaudo and Arianna Loregian},
  journal={Antiviral Research},
  year={2018},
  volume={150},
  pages={130–136}
}
Abstract Currently, there are no therapeutic alternatives to DNA polymerase inhibitors to treat human cytomegalovirus (HCMV) infections, a major threat for immunocompromised patients and pregnant women. Here, we explored the potential to repurpose manidipine dihydrochloride (MND), a calcium antagonist clinically approved to treat hypertension, as a new anti‐HCMV agent. MND emerged in a previous drug repurposing screen to find early inhibitors of HCMV replication, and now we confirm that it… 
13 Citations
The isoquinoline alkaloid berberine inhibits human cytomegalovirus replication by interfering with the viral Immediate Early‐2 (IE2) protein transactivating activity.
TLDR
The characterization of the mechanism of action of a bioactive plant‐derived alkaloid, berberine (BBR), selected in a previous drug repurposing screen expressly devised to identify early inhibitors of HCMV replication, revealed that it compromised the progression of virus cycle at a stage prior to viral DNA replication and Early (E) genes expression, but after Immediate‐Early (IE) proteins expression.
The Antifungal Drug Isavuconazole Inhibits the Replication of Human Cytomegalovirus (HCMV) and Acts Synergistically with Anti-HCMV Drugs.
TLDR
ICZ showed synergistic antiviral activity in vitro when administered in combination with different approved anti-HCMV drugs at clinically relevant doses and paved the way to possible future clinical studies aimed at evaluating the repurposing potential of ICZ in the treatment of HCMV-associated diseases.
The Clinically Approved Antifungal Drug Posaconazole Inhibits Human Cytomegalovirus Replication
TLDR
PCZ is reported to have a broad anti-HCMV activity, being active against different strains, including low-passage-number clinical isolates and strains resistant to viral DNA polymerase inhibitors.
Bright and Early: Inhibiting Human Cytomegalovirus by Targeting Major Immediate-Early Gene Expression or Protein Function
TLDR
An update is provided on the regulation of major IE gene expression and the functions of IE1 and IE2 proteins believed to control all subsequent early and late events in HCMV replication, including reactivation from latency, in part by antagonizing intrinsic and innate immune responses.
Divide et impera: An In Silico Screening Targeting HCMV ppUL44 Processivity Factor Homodimerization Identifies Small Molecules Inhibiting Viral Replication
TLDR
In conclusion, inhibition of ppUL44 dimerization could represent a new class of HCMV inhibitors, complementary to those targeting the DNA polymerase catalytic subunit or the viral terminase complex.
Repurposing approved drugs on the pathway to novel therapies
  • C. Schein
  • Medicine
    Medicinal research reviews
  • 2019
TLDR
Collaboration with medicinal chemists can aid in finding derivatives with better physicochemical properties, specificity, and efficacy, to provide novel therapies for cancers, emerging and rare diseases.
Conflicts over calcium and the treatment of COVID-19
TLDR
Considerable evidence supports the hypothesis that hypocalcemia represents a host defence, and may exert antiviral effects in a similar manner as do CCBs, through interference with calcium metabolism in virus-infected cells.
The emerging role of human cytomegalovirus infection in human carcinogenesis: a review of current evidence and potential therapeutic implications
TLDR
This review will focus on H CMV-related onco-viral mechanisms and the potential of HCMV as a new therapeutic target in HCMv positive cancer forms.
Drug Repurposing for Viral Infectious Diseases: How Far Are We?
TLDR
The main strategies of drug repurposing in antiviral discovery are described, the most promising candidates that could be repurposed to treat viral infections are discussed, and the possible caveats of this trendy strategy of drug discovery are analyzed.
Drug Repurposing Campaigns for Human Cytomegalovirus Identify a Natural Compound Targeting the Immediate-Early 2 (IE2) Protein: A Comment on “The Natural Flavonoid Compound Deguelin Inhibits HCMV Lytic Replication within Fibroblasts”
Human cytomegalovirus (HCMV) is a ubiquitous herpesvirus that establishes a lifelong persistence in the host through both chronic and latent states of infection [...].
...
1
2
...

References

SHOWING 1-10 OF 39 REFERENCES
Design, Synthesis, and Evaluation of WC5 Analogues as Inhibitors of Human Cytomegalovirus Immediate‐Early 2 Protein, a Promising Target for Anti‐HCMV Treatment
TLDR
The quinolone scaffold of the lead compound WC5 was investigated in depth, defining more suitable substituents for each of the scaffold positions explored and identifying novel, potent and nontoxic compounds.
Human cytomegalovirus DNA replication: antiviral targets and drugs
TLDR
This review focuses on HCMV proteins that are directly or indirectly involved in viral DNA replication and represent already established or potential novel antiviral targets, and describes both currently available drugs and new compounds against such protein targets.
Drug Repurposing Approach Identifies Inhibitors of the Prototypic Viral Transcription Factor IE2 that Block Human Cytomegalovirus Replication.
TLDR
Screening of a library of bioactive small molecules led to the identification of several compounds able to inhibit EGFP expression and also HCMV replication with potency in the low-micromolar range, providing proof of concept for identifying small molecules that modulate the activity of a microbial transcription factor to control pathogen replication.
Early inhibitors of human cytomegalovirus: State-of-art and therapeutic perspectives
TLDR
The current knowledge on the initial phases of HCMV replication, their validation as potential novel antiviral targets, and the development of compounds that block such processes are described are described.
Antiviral treatment of cytomegalovirus infection and resistant strains.
TLDR
New antiviral agents are urgently needed with less adverse effects, good oral bioavailability and possibly novel targets or mechanisms of action to avoid cross-resistance and to improve the ability to suppress the selection of resistant virus strains by combination therapy.
The 6-Aminoquinolone WC5 Inhibits Different Functions of the Immediate-Early 2 (IE2) Protein of Human Cytomegalovirus That Are Essential for Viral Replication
TLDR
The results indicate that the overall anti-HCMV activity of WC5 depends on its ability to specifically interfere with the IE2-dependent regulation of viral promoters, and suggest that this mechanism is conserved in murine CMV, thus paving the way for further preclinical evaluation in an animal model.
Kinome Profiling Identifies Druggable Targets for Novel Human Cytomegalovirus (HCMV) Antivirals*
TLDR
Results show the utility of MIB-MS kinome profiling for identifying existing kinase inhibitors that can potentially be repurposed as novel antiviral drugs.
The 6-Aminoquinolone WC5 Inhibits Human Cytomegalovirus Replication at an Early Stage by Interfering with the Transactivating Activity of Viral Immediate-Early 2 Protein
TLDR
Evaluation of viral mRNA and protein expression revealed that WC5 targets an event of the HCMV replicative cycle that follows the transcription and translation of immediate-early genes and precedes those of early and late genes.
Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art
TLDR
This review is focused on HCMV antiviral drug resistance, including the functions of target genes of antivirals, the mechanisms of antiviral resistance, the different mutations in pUL97 and pUL54 that have been identified in either clinical isolates or laboratory strains, and their impact on H CMV susceptibility to antiviral drugs.
Identification of compounds with anti-human cytomegalovirus activity that inhibit production of IE2 proteins
TLDR
Three structurally related 5‐aminopyrazine compounds that inhibited HCMV replication in virus yield reduction assays at low micromolar concentrations likely inhibited transcription from the viral genome and suppressed production of a subset of viral proteins by inhibiting IE2 protein production.
...
1
2
3
4
...